Difei Yang
Stock Analyst at Mizuho
(1.75)
# 3,157
Out of 4,761 analysts
36
Total ratings
27.27%
Success rate
4.35%
Average return
Main Sectors:
Stocks Rated by Difei Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKBA Akebia Therapeutics | Downgrades: Neutral | $6 → $2 | $1.80 | +11.11% | 4 | Mar 31, 2022 | |
| BLUE bluebird bio | Maintains: Buy | $580 → $460 | $4.08 | +11,174.51% | 3 | Sep 22, 2021 | |
| NVCR NovoCure | Maintains: Neutral | $229 → $200 | $22.09 | +805.39% | 6 | Jul 30, 2021 | |
| CASI CASI Pharmaceuticals | Initiates: Buy | $38 | $2.45 | +1,451.02% | 1 | Apr 26, 2021 | |
| FGEN FibroGen | Downgrades: Neutral | $29 | $0.71 | +4,008.23% | 4 | Apr 7, 2021 | |
| QURE uniQure | Upgrades: Buy | $52 | $12.84 | +304.98% | 4 | Apr 1, 2021 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $158 → $160 | $106.28 | +50.55% | 2 | Feb 26, 2021 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $18 → $14 | $3.75 | +273.33% | 4 | Apr 23, 2020 | |
| NKTR Nektar Therapeutics | Upgrades: Buy | $21 → $35 | $0.93 | +3,654.56% | 4 | Feb 3, 2020 | |
| BOLD Boundless Bio | Upgrades: Buy | n/a | $1.96 | - | 2 | Aug 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $7.27 | +285.14% | 1 | Feb 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $1.73 | +1,518.50% | 1 | Sep 27, 2017 |
Akebia Therapeutics
Mar 31, 2022
Downgrades: Neutral
Price Target: $6 → $2
Current: $1.80
Upside: +11.11%
bluebird bio
Sep 22, 2021
Maintains: Buy
Price Target: $580 → $460
Current: $4.08
Upside: +11,174.51%
NovoCure
Jul 30, 2021
Maintains: Neutral
Price Target: $229 → $200
Current: $22.09
Upside: +805.39%
CASI Pharmaceuticals
Apr 26, 2021
Initiates: Buy
Price Target: $38
Current: $2.45
Upside: +1,451.02%
FibroGen
Apr 7, 2021
Downgrades: Neutral
Price Target: $29
Current: $0.71
Upside: +4,008.23%
uniQure
Apr 1, 2021
Upgrades: Buy
Price Target: $52
Current: $12.84
Upside: +304.98%
Sarepta Therapeutics
Feb 26, 2021
Maintains: Buy
Price Target: $158 → $160
Current: $106.28
Upside: +50.55%
Xeris Biopharma Holdings
Apr 23, 2020
Maintains: Buy
Price Target: $18 → $14
Current: $3.75
Upside: +273.33%
Nektar Therapeutics
Feb 3, 2020
Upgrades: Buy
Price Target: $21 → $35
Current: $0.93
Upside: +3,654.56%
Boundless Bio
Aug 8, 2018
Upgrades: Buy
Price Target: n/a
Current: $1.96
Upside: -
Feb 13, 2018
Initiates: Neutral
Price Target: $28
Current: $7.27
Upside: +285.14%
Sep 27, 2017
Initiates: Buy
Price Target: $28
Current: $1.73
Upside: +1,518.50%